Petros Pharmaceuticals, Inc.

OTCPK:PTPI Stock Report

Market Cap: US$257.9k

Petros Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Fady Boctor

Chief executive officer

US$528.2k

Total compensation

CEO salary percentage60.74%
CEO tenure6.3yrs
CEO ownership0.6%
Management average tenureno data
Board average tenure5.4yrs

Recent management updates

Analysis Article • Nov 13

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady...

Recent updates

Analysis Article • Nov 13

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady...
Seeking Alpha • Aug 15

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Petros Pharmaceuticals press release (NASDAQ:PTPI): Q2 GAAP EPS of -$0.10. Revenue of $6.6M (+0.9% Y/Y).
Seeking Alpha • Jul 28

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Private investment group Henry Crown and Company (HCC) will acquire men's health firm Petros Pharmaceuticals (NASDAQ:PTPI) for $3.25 per share in an all-cash transaction for a total equity value of about $67.2M, the companies said on Thursday. The deal value of $3.25 per share represents a 306.25% premium to PTPI's last closing price of $0.80. PTPI shares zoomed on the announcement, more than tripling in value to $2.63. As per the deal, CVF LLC, an affiliate managing HCC's healthcare investments, will acquire all the outstanding shares of PTPI, which will become a privately-owned company at the close of the transaction. PTPI's board has unanimously approved the merger. HCC expects to finance the deal with existing cash on hand. The companies expect the merger to close by early 2023. The merger also includes the acquisition of PTPI's assets including erectile dysfunction (ED) drug Stendra, a treatment candidate for Peyronie's disease called H100 and a line of medical devices for the treatment of ED.
Seeking Alpha • Dec 07

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Petros Pharmaceuticals is developing complementary men’s health therapeutics. The Company’s target lead indications are erectile dysfunction and Peyronie’s disease. Petros recently announced a $10 million public offering of its common stock for $3 per share.

CEO Compensation Analysis

How has Fady Boctor's remuneration changed compared to Petros Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$41m

Dec 31 2025US$528kUS$321k

-US$50m

Sep 30 2025n/an/a

-US$68m

Jun 30 2025n/an/a

-US$70m

Mar 31 2025n/an/a

-US$31m

Dec 31 2024US$740kUS$333k

-US$13m

Sep 30 2024n/an/a

-US$15m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$875kUS$350k

-US$14m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$21m

Dec 31 2022US$682kUS$350k

-US$20m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$1mUS$350k

-US$9m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$468kUS$276k

-US$21m

Sep 30 2020n/an/a

-US$24m

Jun 30 2020n/an/a

-US$29m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$340kUS$208k

-US$33m

Compensation vs Market: Fady's total compensation ($USD528.20K) is about average for companies of similar size in the US market ($USD626.93K).

Compensation vs Earnings: Fady's compensation has been consistent with company performance over the past year.

CEO

Fady Boctor (47 yo)

6.3yrs
Tenure
US$528,204
Compensation

Mr. Fady Boctor, MBA, has been the President and Chief Commercial Officer of Petros Pharmaceuticals, Inc. since 2020. Mr. Boctor has experience in the pharmaceutical industry, across a wide array of functi...

Board Members

NamePositionTenureCompensationOwnership
Joshua Silverman
Executive Chairman of the Board5.4yrsUS$792.25k5.27%
$ 13.6k
Wayne Walker
Independent Director5.4yrsUS$140.65k0.61%
$ 1.6k
Bruce Bernstein
Independent Director5.4yrsUS$278.80k2.22%
$ 5.7k
5.4yrs
Average Tenure
62yo
Average Age

Experienced Board: PTPI's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 18:02
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Petros Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nazibur RahmanMaxim Group